NovaBay Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $2,441 | $2,400 | $2,631 | $3,727 |
Gross Profit | 1,593 | 1,592 | 1,794 | 1,815 |
EBITDA | -979 | -1,042 | -3,078 | -748 |
EBIT | -1,074 | -1,053 | -3,090 | -798 |
Net Income | -1,212 | -1,585 | -3,214 | -4,107 |
Net Change In Cash | 2,441 | 2,400 | 2,631 | 3,727 |
Free Cash Flow | -1,948 | -676 | -1,593 | -203 |
Cash | 776 | 751 | 1,823 | 3,130 |
Basic Shares | 3,710 | 1,155 | 704 | 197 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $14,726 | $14,404 | $8,421 | $9,934 |
Gross Profit | 7,895 | 7,781 | 5,645 | 5,964 |
EBITDA | -4,800 | -7,197 | -8,743 | -6,375 |
EBIT | -5,003 | -7,680 | -8,862 | -6,426 |
Net Income | -9,640 | -16,265 | -6,559 | -11,039 |
Net Change In Cash | 14,726 | 14,404 | 8,421 | 9,934 |
Cost of Revenue | 5,015 | |||
Free Cash Flow | -4,150 | -6,766 | -9,244 | -4,747 |
Cash | 3,130 | 5,362 | 7,504 | 11,952 |
Basic Shares | 120 | 46 | 35 | 28 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.33 |
2024-06-30 | -$1.37 |
2024-03-31 | -$0.15 |
2023-12-31 | -$1.33 |
